Rheumatoid arthritis is a chronic autoimmune disease in which the immune system attacks the lining of the joints, causing persistent inflammation that can destroy cartilage and bone over time. Unlike osteoarthritis, which results from mechanical wear, RA is driven by immune dysfunction and often strikes symmetrically, affecting the same joints on both sides of the body. The disease goes well beyond stiff fingers, though, with potential effects on the lungs, heart, and mental health that shape how doctors approach treatment today.
What Happens Inside an Affected Joint
The immune system in RA produces antibodies against the body’s own tissues. Two of the most studied are rheumatoid factor and anti-citrullinated protein antibodies, both of which target proteins found inside and outside the joints.1PubMed. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction These antibodies help fuel a cycle of inflammation in the synovial membrane, the thin tissue that lines each joint capsule. Over time, the inflamed synovium thickens into an aggressive tissue called the pannus, which invades cartilage, the underlying bone, and surrounding soft tissue.2PubMed Central. The pathogenesis of rheumatoid arthritis in radiological studies. Part I: Formation of inflammatory infiltrates within the synovial membrane Joint destruction in RA is not caused by a single process; it involves imbalances among several signaling systems that regulate bone-resorbing cells and cartilage repair.
What triggers this autoimmune cascade remains an active area of research. Genetics play a role, particularly certain variants of the HLA-DRB1 gene. Smoking is a well-established environmental risk factor. Interestingly, antibodies against the gum-disease bacterium Porphyromonas gingivalis have been linked to RA risk even more strongly than smoking in some analyses, and there appear to be interactions among the bacterium, smoking, and genetic susceptibility in people who are antibody-positive.3PubMed Central. Antibodies to Porphyromonas gingivalis Indicate Interaction Between Oral Infection, Smoking, and Risk Genes in Rheumatoid Arthritis Etiology This connection between oral health and joint disease is one of the more surprising findings in RA research over the past decade.
Recognizing the Early Signs
RA typically starts with an insidious onset of pain and symmetric swelling in the small joints. The hands are the most common early target, with tenderness and swelling across the knuckles, the middle finger joints, and the wrists.4PubMed. The clinical features of rheumatoid arthritis Early on, X-rays often look normal even though there is already significant inflammation and reduced range of motion. This is part of why the disease can be tricky to catch right away.
Morning stiffness is one of the hallmark symptoms. People with RA describe joints that feel locked up upon waking, and this stiffness typically lasts at least an hour before starting to ease. MRI studies show that inflammation of the tendon sheaths in the small joints is an early feature of the disease and contributes directly to that morning stiffness.5PubMed Central. Contribution of tenosynovitis of small joints to the symptom morning stiffness in patients presenting with undifferentiated and rheumatoid arthritis If you wake up with stiff, swollen fingers that take well over an hour to loosen, that pattern is worth bringing to a doctor’s attention, particularly if it persists for weeks.
Not everyone fits the textbook picture, though. Some people develop RA in a single large joint first. Others experience systemic symptoms like fatigue and low-grade fever before joint swelling becomes obvious. The variability in presentation is one reason diagnosis sometimes takes months.
When RA Reaches Beyond the Joints
RA is a systemic disease, meaning the inflammation does not stay confined to joints. Extra-articular manifestations can affect the skin, eyes, heart, blood vessels, nerves, and kidneys.6EMJ Rheumatology. Extra-Articular Manifestations of Rheumatoid Arthritis, Now Rheumatoid nodules, firm bumps that form under the skin near affected joints, are the most common of these. People who develop nodules within the first two years of diagnosis tend to be at higher risk for more serious complications like vasculitis and lung disease.
Lung involvement deserves special attention. RA-associated interstitial lung disease, where inflammation leads to scarring in lung tissue, is a major contributor to mortality in RA patients and has not declined in frequency the way some other complications have.7PubMed. Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis Beyond scarring, RA can cause airway disease, pulmonary nodules, and fluid around the lungs.8PubMed. Review of pulmonary manifestations of rheumatoid arthritis Respiratory symptoms like a persistent dry cough or unexplained shortness of breath in someone with RA should prompt evaluation rather than being chalked up to aging or deconditioning.
Cardiovascular disease is another significant concern. The chronic inflammation of RA and the process that drives atherosclerosis share overlapping pathways, which means people with RA carry an elevated risk of heart attack and stroke beyond what traditional risk factors alone would predict.9Nature Reviews Rheumatology. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease Controlling RA inflammation is, in part, a cardiovascular strategy.
How RA Is Diagnosed
There is no single test that confirms RA. Diagnosis relies on a combination of symptoms, physical examination, blood work, and sometimes imaging. The two most useful blood markers are rheumatoid factor and anti-cyclic citrullinated peptide antibodies. Anti-CCP testing is more specific for RA than rheumatoid factor, meaning it is less likely to flag positive in someone who does not actually have the disease. A meta-analysis of diagnostic accuracy studies found that anti-CCP had a specificity of about 95%, compared to roughly 85% for rheumatoid factor.10PubMed. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis
Used together, the two tests perform better than either one alone. Their combined positive predictive value approaches 100%, and the combination also helps identify patients who are likely to have a more severe disease course.11PubMed Central. A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis Both tests are incorporated into the classification criteria that rheumatologists use. Still, roughly a third of people with RA are “seronegative,” meaning they test negative for both antibodies. In those cases, diagnosis leans more heavily on clinical findings and imaging.
Methotrexate as the Foundation of Treatment
Methotrexate has been the backbone of RA treatment for about four decades and remains the global standard first-line drug.12PubMed. Application and pharmacological mechanism of methotrexate in rheumatoid arthritis It belongs to a class called conventional disease-modifying antirheumatic drugs, or DMARDs. These drugs do not just mask symptoms; they slow the underlying disease process and reduce joint damage over time.
How methotrexate works in RA is actually more complicated than its original use as a cancer drug might suggest. Research shows that in RA patients, certain metabolic pathways related to folate processing are abnormally ramped up, and methotrexate treatment normalizes them back to the levels seen in healthy people.13PubMed. Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis It also promotes the accumulation of adenosine, a molecule with anti-inflammatory effects, and influences several other immune-related signaling pathways.
Side effects are the main limitation. Nausea, mouth sores, liver enzyme elevations, and reduced blood cell counts are the most common concerns. Taking folic acid supplements alongside methotrexate is the most effective strategy for reducing these side effects, and it is now standard practice.14PubMed. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity Regular blood monitoring is part of life on methotrexate, but most people tolerate the drug well enough to stay on it for years.
Biologics and JAK Inhibitors
When methotrexate alone is not enough to control the disease, doctors typically add a biologic drug. Biologics are engineered proteins, usually given by injection or infusion, that target specific parts of the immune system. The first major class blocks tumor necrosis factor (TNF), a key inflammatory molecule. Other biologics target interleukin-6, B cells, or T-cell activation pathways. In registry analyses comparing TNF inhibitors to IL-6 inhibitors in people who had already tried a biologic, the two classes performed similarly on most measures of disease activity and patient-reported outcomes.15PubMed Central. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis
A newer class of oral drugs called JAK inhibitors offers an alternative to injected biologics. These drugs block Janus kinase enzymes, which sit inside cells and relay signals from multiple inflammatory molecules at once. Tofacitinib was the first to gain widespread approval, and baricitinib followed with strong efficacy data. Both work in patients who have not responded well to either conventional DMARDs or biologics.16PubMed. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis The convenience of a pill rather than an injection appeals to many patients, though JAK inhibitors carry their own safety considerations, including an increased risk of blood clots and certain infections, that have led regulators to recommend them mainly after a biologic has been tried.
Corticosteroids and the Bridging Problem
Corticosteroids like prednisone are sometimes used as a “bridge” to control inflammation quickly while slower-acting DMARDs ramp up. They are remarkably effective at tamping down symptoms in the short term, but long-term use brings well-known complications including bone thinning, weight gain, and elevated blood sugar. The challenge is getting off them.
Research shows that stopping oral corticosteroid bridging therapy, even in patients who had achieved remission on methotrexate, was associated with a higher risk of disease flare. In one study, about 43% of patients on oral corticosteroid bridging experienced at least one flare within a year, compared to about 24% of those bridged with steroid injections directly into affected joints.17PubMed Central. Flare risk after oral glucocorticoid bridging with methotrexate or intra-articular bridging with triple therapy in early rheumatoid arthritis An individual patient data meta-analysis found that about 30% of patients were still using corticosteroids continuously three or more months after bridging was supposed to end, when measured two years from baseline.18Annals of the Rheumatic Diseases. Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis This “bridging that never ends” phenomenon is something rheumatologists actively work to prevent, because the cumulative harms of corticosteroids add up.
The Treat-to-Target Approach
Modern RA management follows a strategy called treat-to-target, which means therapy is regularly adjusted with a clear goal in mind, usually either remission or low disease activity.19PubMed. Theory & practice of Treat-to-Target (T2T) in rheumatoid arthritis Rather than starting a drug and hoping for the best, doctors measure disease activity at regular intervals, commonly every three months, and escalate treatment if the target is not met.
Evidence supports this approach. Systematic reviews have found that treat-to-target strategies increase remission rates in early RA and improve outcomes in people with established disease as well.20SN Comprehensive Clinical Medicine. Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis The practical implication for patients is that “good enough” is not the goal. If you still have meaningful joint swelling or pain, that is a signal to discuss stepping up treatment rather than simply managing symptoms indefinitely.
Exercise and Diet
A common fear among people with RA is that exercise will worsen their joints. Research consistently shows the opposite. Exercise training has been shown to improve function, reverse the muscle wasting that accompanies chronic inflammation (sometimes called rheumatoid cachexia), and does not make disease activity worse.21PubMed Central. Benefits of exercise in rheumatoid arthritis Resistance training in particular appears to help. In case-level data, strength training in RA patients increased knee extensor strength by about 14%, grew muscle mass, and substantially increased muscle fiber size while reducing markers of muscle cell death.22PubMed Central. Resistance exercise reduces skeletal muscle cachexia and improves muscle function in rheumatoid arthritis Given the cardiovascular risks that come with RA, regular physical activity serves double duty.
On the dietary side, omega-3 fatty acids from fish oil are the best-studied nutritional intervention. Clinical studies suggest that omega-3 supplementation can modestly reduce the number of swollen and tender joints.23PubMed Central. The Effect of Omega-3 Fatty Acids on Rheumatoid Arthritis A systematic review of dietary interventions found that an anti-inflammatory diet combined with fish oil supplementation led to significant reductions in inflammatory markers and allowed some patients to reduce their corticosteroid doses.24PubMed Central. Dietary Interventions with or without Omega-3 Supplementation for the Management of Rheumatoid Arthritis: A Systematic Review Diet is not a substitute for medication, but it can be a useful add-on. The evidence is strongest for omega-3s and for eating patterns that emphasize anti-inflammatory foods like vegetables, fruit, and whole grains.
Depression, Anxiety, and Fatigue
Many people with RA report debilitating fatigue, low mood, and anxiety that feel out of proportion to their joint symptoms. Research suggests these are not simply psychological reactions to living with chronic pain. Instead, the depression, anxiety, and chronic-fatigue-like symptoms that accompany RA appear to be driven by the same immune and inflammatory pathways that cause joint damage.25PubMed Central. Pathway Phenotypes Underpinning Depression, Anxiety, and Chronic Fatigue Symptoms Due to Acute Rheumatoid Arthritis In one analysis, roughly 70% of the variance in the shared core of psychological and physical RA symptoms was explained by immune-inflammatory pathways, autoantibodies, and opioid receptor levels. In practical terms, getting RA inflammation under better control often improves fatigue and mood, and mental health symptoms that persist despite well-controlled joints may warrant their own treatment.
Pregnancy and RA
Planning a pregnancy with RA requires careful coordination with a rheumatologist, mainly because several effective RA drugs must be stopped before conception. Methotrexate and leflunomide are both known to cause birth defects and need to be discontinued well in advance of a planned pregnancy.26PubMed. The treatment of rheumatoid arthritis during pregnancy Rituximab and abatacept are also recommended to be stopped, not because they are proven teratogenic, but because their safety during pregnancy has not been established.27Nature Reviews Rheumatology. Management of RA medications in pregnant patients
That still leaves options. Sulfasalazine, hydroxychloroquine, azathioprine, and low-dose corticosteroids can be used throughout pregnancy. NSAIDs are considered safe until the third trimester, when they should be avoided because they can affect fetal heart development and amniotic fluid levels.28PubMed. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management Some women experience a natural improvement in RA symptoms during pregnancy, but this is not universal, and disease flares during pregnancy or after delivery are common. The key principle is to stabilize the disease on pregnancy-compatible medications before conceiving rather than scrambling to adjust treatment after a positive test.
When Surgery Is Considered
Modern drug therapy has reduced the need for surgery in RA, but it has not eliminated it. When chronic inflammation causes permanent cartilage and bone damage, the resulting joint instability and pain sometimes cannot be managed with medication alone. Surgical options range from preventive procedures designed to halt further destruction to full joint replacement after a joint has been severely damaged.29PubMed. Treatment strategies in surgery for rheumatoid arthritis Synovectomy, the surgical removal of inflamed synovial tissue, can help preserve a joint before irreversible damage sets in. For end-stage joints, particularly in the hips and knees, total joint replacement reliably restores function and eliminates pain. Hand and wrist surgery is also common in RA, addressing tendon ruptures and correcting the characteristic deformities that develop when joints have been chronically inflamed.
How RA Differs from Juvenile Idiopathic Arthritis
Parents sometimes worry that a child with joint inflammation has “childhood RA.” The pediatric counterpart is called juvenile idiopathic arthritis, and while it shares some features with adult RA, it is a distinct condition. Children with polyarticular JIA are less likely to test positive for rheumatoid factor or anti-CCP antibodies, and fewer than half of them meet the classification criteria used for adult RA.30PubMed Central. Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis JIA also encompasses several subtypes with different patterns of joint involvement and different systemic features. The treatment toolbox overlaps significantly with adult RA, including methotrexate and biologics, but the disease trajectory, monitoring approach, and long-term considerations differ enough that pediatric rheumatologists manage these patients separately. Adults who were diagnosed with JIA in childhood and transition to adult care sometimes fall through the cracks, because their disease behaves differently from typical adult-onset RA even though the treatments look similar on paper.